Global Ingredient Risk Index Mineral

Phosphorus (Phosphate)

Dibasic calcium phosphate / Disodium phosphate

Also known as: Phosphate, phosphorus, calcium phosphate, disodium phosphate

23 მარ 2026

LOW RISK 3.5/10 How?

This ingredient is classified as unclassified risk (GIRI score: 3.5/10).

Known Safety Concerns

Hyperphosphataemia in chronic kidney disease — dangerous
Excess disrupts calcium-phosphorus balance — secondary hyperparathyroidism
High phosphate intake associated with cardiovascular mortality in renal patients
Frequently overlooked in supplement labels

Contraindications

Hyperphosphataemia in chronic kidney disease — dangerous
Excess disrupts calcium-phosphorus balance — secondary hyperparathyroidism

═══════════════════════════════════════════════════════════════════════ -->

Information not yet available for this ingredient profile.

Phosphorus is an essential mineral widely added to supplements and fortified foods. Dietary phosphate excess is common in processed food consumers. Supplemental phosphate at high doses disrupts the calcium-phosphorus ratio, causing secondary hyperparathyroidism and bone resorption. Particularly dangerous in chronic kidney disease where phosphate excretion is impaired.

Scientific Name: Dibasic calcium phosphate / Disodium phosphate

Information not yet available for this ingredient profile.

SETI Score 50/100

Risk Level High risk

Scientific Confidence Low

Evidence Strength Limited

Key Benefit Mineral

Key Safety Concern Hyperphosphataemia in chronic kidney disease — dangerous

Evidence Reviewed 10 PubMed studies

Scientific Confidence Low

Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100

Risk Level High risk

Evidence Strength Limited

Main Benefit Mineral

Main Safety Concern Hyperphosphataemia in chronic kidney disease — dangerous

Ingredient Phosphorus (Phosphate)

Scientific name Dibasic calcium phosphate / Disodium phosphate

Scientific Evidence Overview

10 studies reviewed
0 high-quality studies (meta-analysis or RCT)
Main clinical benefit observed: Mineral
Evidence consistency: High consistency across studies (100%)

Safety Signals

Hyperphosphataemia in chronic kidney disease — dangerous
Excess disrupts calcium-phosphorus balance — secondary hyperparathyroidism
High phosphate intake associated with cardiovascular mortality in renal patients
Frequently overlooked in supplement labels

Evidence Strength Limited

Final Scientific Assessment

The available scientific evidence for Phosphorus (Phosphate) indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Phosphorus (Phosphate)

Evidence reviewed 10 peer-reviewed studies (last 10 years)

Scientific name Dibasic calcium phosphate / Disodium phosphate

50 /100

Total SETI Score

High risk

Evidence quality	10/40
Evidence consistency	20/20
Safety signals	0/20
Study recency	10/10
Evidence transparency	10/10

Evidence Summary

10 studies reviewed
0 high-quality studies (meta-analysis or systematic review)
0 studies identified benefits or no safety concern (GREEN)
10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 23 მარ 2026, 15:13

Evidence Distribution

10 Other / unclassified

Observational / other LOW evidence YELLOW
Characteristics of Patients with Primary Hyperparathyroidism with Localization Failure of the Causative Parathyroid Gland: A Clinical Report and Literature Review. ↗

PMID 41260647 ↗

Journal Intern Med

Year 2025

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41260647/

Takedani K et al.. Characteristics of Patients with Primary Hyperparathyroidism with Localization Failure of the Causative Parathyroid Gland: A Clinical Report and Literature Review.. Intern Med. 2025. PMID:41260647.
Observational / other LOW evidence YELLOW
Pharmacodynamic Modeling of Cinacalcet in Secondary Hyperparathyroidism: Efficacy and Influencing Factors Analysis. ↗

PMID 40160292 ↗

Journal J Endocr Soc

Year 2025

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/40160292/

Wang Z et al.. Pharmacodynamic Modeling of Cinacalcet in Secondary Hyperparathyroidism: Efficacy and Influencing Factors Analysis.. J Endocr Soc. 2025. PMID:40160292.
Observational / other LOW evidence YELLOW
Alterations in salivary profile in individuals with dental caries and/or obesity: A systematic review and meta-analysis. ↗

PMID 39505293 ↗

Journal J Dent

Year 2024

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/39505293/

Deng Q et al.. Alterations in salivary profile in individuals with dental caries and/or obesity: A systematic review and meta-analysis.. J Dent. 2024. PMID:39505293.
Observational / other LOW evidence YELLOW
Impact of nature-based solutions on sustainable development goals in Mediterranean agroecosystems: A meta-analysis. ↗

PMID 39476663 ↗

Journal J Environ Manage

Year 2024

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/39476663/

Rodrigues MS et al.. Impact of nature-based solutions on sustainable development goals in Mediterranean agroecosystems: A meta-analysis.. J Environ Manage. 2024. PMID:39476663.
Observational / other LOW evidence YELLOW
Biochar-based fixed filter columns for water treatment: A comprehensive review. ↗

PMID 39278474 ↗

Journal Sci Total Environ

Year 2024

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/39278474/

Bui VKH et al.. Biochar-based fixed filter columns for water treatment: A comprehensive review.. Sci Total Environ. 2024. PMID:39278474.
Observational / other LOW evidence YELLOW
La-MOFs in situ loaded Al(2)O(3) particles for effective removal of phosphate in water: characterization, application potential analysis, and mechanism. ↗

PMID 37796353 ↗

Journal Environ Sci Pollut Res Int

Year 2023

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/37796353/

Ai H et al.. La-MOFs in situ loaded Al(2)O(3) particles for effective removal of phosphate in water: characterization, application potential analysis, and mechanism.. Environ Sci Pollut Res Int. 2023. PMID:37796353.
Observational / other LOW evidence YELLOW
Recovery trajectories of the bacterial community at distances in the receiving river under wastewater treatment plant discharge. ↗

PMID 36368207 ↗

Journal J Environ Manage

Year 2023

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/36368207/

Zhang L et al.. Recovery trajectories of the bacterial community at distances in the receiving river under wastewater treatment plant discharge.. J Environ Manage. 2023. PMID:36368207.
Observational / other LOW evidence YELLOW
A Review of Current Evidence on the Relationship between Phosphate Metabolism and Metabolic Syndrome. ↗

PMID 36364791 ↗

Journal Nutrients

Year 2022

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/36364791/

Wong SK. A Review of Current Evidence on the Relationship between Phosphate Metabolism and Metabolic Syndrome.. Nutrients. 2022. PMID:36364791.
Observational / other LOW evidence YELLOW
[Microbial Diversity and Influencing Factors in a Small Watershed in Winter]. ↗

PMID 33124245 ↗

Journal Huan Jing Ke Xue

Year 2020

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/33124245/

Zhu JS et al.. [Microbial Diversity and Influencing Factors in a Small Watershed in Winter].. Huan Jing Ke Xue. 2020. PMID:33124245.
Observational / other LOW evidence YELLOW
Predicting ecosystem state changes in shallow lakes using an aquatic ecosystem model: Lake Hinge, Denmark, an example. ↗

PMID 32363772 ↗

Journal Ecol Appl

Year 2020

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/32363772/

Andersen TK et al.. Predicting ecosystem state changes in shallow lakes using an aquatic ecosystem model: Lake Hinge, Denmark, an example.. Ecol Appl. 2020. PMID:32363772.

Q × L × D × S × 10 = 3.5 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

Benefit

Risk

50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 3.5 / 10

Final GIRI Score for Phosphorus (Phosphate). Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.

LOW RISK 3.5/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0

MODERATE
3.0–5.5

HIGH
5.5–7.5

CRITICAL
7.5–10

3.5

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for Phosphorus (Phosphate)

A score of 3.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

0 approved references.

Limited — mostly case reports or animal studies (Level 4–5).

Neutral or mixed — benefit and risk signals roughly balanced.

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

Level	Score	Meaning
LOW	0.0 – 2.9	Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE	3.0 – 5.4	Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH	5.5 – 7.4	Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL	7.5 – 10	Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

Phosphorus (Phosphate)

Safety Profile

Known Safety Concerns

Contraindications

Interactions

Evidence and Scientific Findings

Ingredient Overview

Biological and Chemical Classification

Mechanism of Action

Clinical Evidence of Effectiveness

Pharmacokinetics

Recommended Dosage

SETI — Scientific Evidence Transparency Index

Executive Summary — Ingredient Assessment

Evidence Summary

Evidence Policy

Evidence Distribution

Score Transparency

Risk Level Classification

What drove the Low classification for Phosphorus (Phosphate)

ბოლო სიახლეები

500მლ პლასტმასის წყლის ბოთლები: ფარული საზოგადოებრივი ჯანმრთელობის რისკები

სკოლამდელი განათლება – მნიშვნელობა და გამოწვევები

ბავშვის უფლებები სკოლაში

პოპულარული ამბები

საუკეთესო ფილმები კულინარიის მოყვარულებისთვის

როგორ იყენებენ ახალგაზრდები ხელოვნურ ინტელექტს – სტუდენტების ხმა

კატეგორიები

ჩვენ შესახებ

გამოგვყევი სოციალურ ქსელებში